Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy

Lee, Samantha C., Feenstra, John and Georghiou, Paul R. (2014) Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Reports, . doi:10.1136/bcr-2014-204950


Author Lee, Samantha C.
Feenstra, John
Georghiou, Paul R.
Title Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy
Journal name BMJ Case Reports   Check publisher's open access policy
ISSN 1757-790X
Publication date 2014-06-02
Year available 2014
Sub-type Article (original research)
DOI 10.1136/bcr-2014-204950
Open Access Status
Total pages 1
Place of publication London, United Kingdom
Publisher BMJ Publishing Group
Language eng
Formatted abstract
Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib.
Q-Index Code CX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 Jun 2014, 00:29:08 EST by System User on behalf of School of Medicine